<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893710</url>
  </required_header>
  <id_info>
    <org_study_id>IPPB Biobank</org_study_id>
    <secondary_id>University of Heidelberg</secondary_id>
    <nct_id>NCT01893710</nct_id>
  </id_info>
  <brief_title>International (Pediatric) Peritoneal Biobank</brief_title>
  <official_title>International (Pediatric) Peritoneal Biobank</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Within few years the peritoneal membrane of adult peritoneal dialysis (PD) patients undergoes
      substantial morphological transformation, including progressive fibrosis, vasculopathy and
      neoangiogenesis. Ultrafiltration capacity steadily declines and ultimately results in PD
      failure. In children, peritoneal biopsies demonstrating PD associated alterations have not
      yet been obtained. They, however, should be particularly informative, since secondary tissue
      and vascular pathology related to ageing or diabetes is absent.

      An international, prospective peritoneal membrane biopsy study in children on PD will
      therefore be performed. Biopsies will be obtained at time of PD catheter insertion, on
      occasion of intercurrent abdominal surgery (e.g. hernia repair, catheter exchange) and at
      time of renal transplantation. Quantitative histomorphometry and tissue protein expression
      analyses will be correlated with time integrated PD treatment modalities and functional
      characteristics as well as inflammatory and cardiovascular comorbidity surrogate parameter.
      Blood will be obtained during clinical routine sampling. Biopsies will be obtained during
      clinically indicated operations, without substantially increasing operation time and
      associated surgical risks. The detailed histomorphometry of the PD membrane will give
      additional information, potentially impacting on the individual PD regime.

      3/2018: The analyses of the pediatric PD biopsy demonstrated early and major transformation
      of the peritoneal membrane with neutral pH low GDP fluids, and significant vasculopathy
      already in children with CKD stage 5, further progressing with PD. The underlying mechanisms
      are partly understood, only. In view of these major findings and the numerous open questions,
      collection of biosamples will be continued in children and also in adult PD patients. The
      following questions will be addressed: Molecular counterparts of peritoneal
      semi-permeability, solute and water transport (beyond AQP1), pathomechanisms and molecular
      and functional impact of peritoneal transformation with low and high GDP fluids, and the
      respective pathomechanisms and molecular and functional impact of vascular disease in CKD and
      with different PD fluids. The impact of renal transplantation following PD will be assessed
      in a subgroup of patients with tenckhoff catheter removal several weeks after transplantation
      and a functioning graft.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please see study protocol and

      http://www.pedpd.org
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">October 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Peritoneal vasculopathy (lumen vessel ratio)</measure>
    <time_frame>Two years (Mean PD treatment time)</time_frame>
    <description>Digital quantification of degree of vasculopathy, i.e the lumen vessel ratio. Healthy children have a L/V ratio of about 0.7. lower values represent vasculopathy with lumen narrowing, 0 is complete obliteration of the vessel.
This measurements will be accompanied by molecular analysis of pathomechanisms (including omics Technology)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of vessels per peritoneal membrane area (per mm²)</measure>
    <time_frame>at time of catheter insertion, intercurrent abdominal surgery and at time of renal transplantation</time_frame>
    <description>Digital histomorphometry of small vessel density per mm² submesothelial section area analysed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Submesothelial thickness (µm)</measure>
    <time_frame>2 years (average PD duration)</time_frame>
    <description>Digital imaging analysis of submesothelial thickness as a marker of peritoneal fibrosis (distance between mesothelium and adjacent muscle/adipos tissue)</description>
  </other_outcome>
  <other_outcome>
    <measure>Submesothelial lymphocyte, macrophage, MMT cell count</measure>
    <time_frame>2 years (mean PD duration)</time_frame>
    <description>Quantification of peritoneal leucocyte Infiltration, i.e. number of CD45 positive lymphocytes and CD68 positive macrophages per mm² of submesothelial section area . The number of cells that underwent mesothelial-mesenchymal transition per mm² submesothelial section are quantified by immunohistochemical co-staining of mesothelial and fibroblast marker (cytokeratin and FSP1).</description>
  </other_outcome>
  <other_outcome>
    <measure>Peritoneal VEGF and pSMAD abundance</measure>
    <time_frame>2 years (mean PD duration)</time_frame>
    <description>Key cytokines involved in peritoneal membrane transformation will be measured immunohistochemically. These are VEGF and TGF-beta induced p-SMAD (%positive area per section area analysed).</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Peritoneal Dialysis Complication</condition>
  <condition>Transplantation</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>'Biopsy sampling': Peritoneal biopsies without kidney disease, i.e. diseases not related to the kidney and not affecting the peritoneum. This group is accomplished.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic kidney disease</arm_group_label>
    <description>Samples will obtained from patients with chronic kidney disease stage 5 (at time of catheter Insertion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <description>Patients on PD with different PD fluids and intercurrent abdominal surgery and at time of renal transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post PD and with functioning graft</arm_group_label>
    <description>Samples will also be collected and analysed from patients with renal transplantation after PD at time of and tenckhoff catheter removal several weeks after Tx or other intercurrent abdominal surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy sampling</intervention_name>
    <description>Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.
Biopsy sampling will be performed in all groups. This is an observational not an interventional trial.</description>
    <arm_group_label>Peritoneal dialysis</arm_group_label>
    <arm_group_label>Post PD and with functioning graft</arm_group_label>
    <arm_group_label>chronic kidney disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Parietal ond omental peritoneal membrane specimen will be collected in all groups
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        See eligibility data
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age 0 to 90 years

          -  CKD 5D, peritoneal dialysis and

          -  Patients with normal renal function and elective abdominal surgery due to limited
             abdominal pathology (such as hernia repair, gallstones….)

          -  Patients post PD and post Tx

          -  Oral and written consent

          -  Ability to consent of the adult patient and of the parents and legal guardian of
             patients not yet of legal age, respectively

        Exclusion Criteria:

          -  Abdominal adhesions, malformation and inflammation beyond PD induced changes

          -  Patients with disseminated tumour disease

          -  Patients with critical heart failure and other medical conditions, where the
             additional procedure may confer an increased increase risk

          -  Pregnancy

          -  Preterm babies (below 37 weeks of gestational age)

          -  Serum hemoglobin &lt; 10 g/dl in newborns and &lt; 8 g/dl in children and adults
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus P Schmitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Heidelberg, Center for Pediatric and Adolescent Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claus P Schmitt, Prof</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>39313</phone_ext>
    <email>claus.peter.schmitt@med.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley A. Warady, MD</last_name>
      <phone>816-234-3010</phone>
      <email>bwarady@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley A. Warady, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children´s Hospital of Philadelphia</name>
      <address>
        <city>Narberth</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Arbeiter, MD</last_name>
      <phone>+43 1404003257</phone>
      <email>klaus.arbeiter@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Klaus Arbeiter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9890</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Van de Walle, MD</last_name>
      <phone>+32 93322483</phone>
      <email>Johan.VandeWalle@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Johan Van de Walle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children`s Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karel Vondrak, MD</last_name>
      <phone>+42 0224432078</phone>
      <email>8080@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Karel Vondrak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie Pédiatrique, Hôpital Femme Mere Enfant</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Ranchin, MD</last_name>
      <phone>+33 427856129</phone>
      <email>bruno.ranchin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Ranchin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children`s Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariane Zaloszyc, MD</last_name>
      <phone>+333388127742</phone>
      <email>ariane.zaloszyc@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Ariane Zaloszyc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine I (Nephrology), University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>BW</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Klein, MD</last_name>
      <phone>+49 62215639776</phone>
      <email>katrin.klein@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children`s Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children`s Hospital</name>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Taylan, MD</last_name>
      <phone>+49 2214784391</phone>
      <email>christina.taylan@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Christina Taylan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children`s Hospital</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Büscher, MD</last_name>
      <phone>+49 201 723-2738</phone>
      <email>Rainer.Buescher@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Rainer Büscher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKE, University Children´s Hospital</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children`s Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Sallay, MD</last_name>
      <phone>+36 13343186</phone>
      <email>sallay.peter@med.semmelweis-univ.hu</email>
    </contact>
    <investigator>
      <last_name>Peter Sallay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children`Hospital</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children`s Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Testa, MD</last_name>
      <phone>+39 0257992471</phone>
      <email>saratesta@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Sara Testa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Nephrology, Dialysis and Transplant Unit</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University children`s Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rimante Cerkauskiene, MD</last_name>
      <phone>+37 052720427</phone>
      <email>rimantec@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Rimante Cerkauskiene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paediatric CAPD unit, Kuala Lumpur Hospital</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krakow, Jagiellonian University Medical College</name>
      <address>
        <city>Krakow</city>
        <zip>30663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorota Drozdz, MD</last_name>
      <phone>+48 12 658 11 59</phone>
      <email>dadrozdz@cm-uj.krakow.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Materno-Infantil Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gema Ariceta, MD</last_name>
      <phone>+34 934893082</phone>
      <email>gariceta@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Gema Ariceta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Inselspital, Bern University Hospital and University of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children`s Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aysun K Bayazit, MD</last_name>
      <phone>+90 3223386935</phone>
      <email>ayskar@cu.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Aysun K Bayazit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cerrahpasa School of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Lebanon</country>
  </removed_countries>
  <link>
    <url>http://www.pedpd.org</url>
    <description>International Pediatric Peritoneal Dialysis Network</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 27, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2013</study_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Claus Peter Schmitt</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>peritoneal dialysis</keyword>
  <keyword>parietal peritoneum</keyword>
  <keyword>omentum</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>vasculopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

